| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 8 | -65.5K | 100% | $2.99 | -$196K |
| Net | -8 | -65.5K | -100% | -$196K |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| John Thomas | Director | $2.46M | -$50K | -1.99% | Dec 1, 2025 |
| Qian Zhang | Associate VP, Research | $1.98M | Feb 17, 2023 | ||
| Thomas Zindrick | President and CEO, Director | $1.86M | -$64.9K | -3.37% | Sep 1, 2025 |
| Aladar Szalay | 10%+ Owner | $1.55M | Sep 12, 2024 | ||
| Joseph Cappello | Chief Technical Officer | $537K | -$28.6K | -5.05% | Sep 1, 2025 |
| Yong Yu | SVP, Clinical Development | $504K | -$16.3K | -3.13% | Sep 1, 2025 |
| John W. Smither | Director | $252K | Aug 27, 2025 | ||
| Mary Mirabelli | Director | $246K | Aug 27, 2025 | ||
| Ralph Smalling | Head of Regulatory | $239K | -$9.55K | -3.85% | Sep 1, 2025 |
| James L. Tyree | Director | $229K | -$8.51K | -3.59% | Aug 27, 2025 |
| Lourie S. Zak | Chief Financial Officer | $193K | -$4.92K | -2.49% | Dec 18, 2024 |
| Gabe Woodward | Director | $175K | Feb 17, 2023 | ||
| Sean Ryder | General Counsel | $139K | -$13.1K | -8.59% | May 12, 2025 |
| Caroline Jewett | Head of Quality | $34.3K | Feb 19, 2024 | ||
| Doug Samuelson | Vice President, Finance | $32.6K | Sep 11, 2023 | ||
| Paul Scigalla | Chief Medical Officer | Oct 18, 2024 | |||
| Eric Groen | General Counsel & Secretary | Jul 1, 2025 | |||
| Matthew Pulisic | Chief Financial Officer | Jan 31, 2025 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|